Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497078 | 0.86 | DRD1 (0.49) | ALDH1A3DRD1HSD17B10AHRERN1 | |
| SCHEMBL3154943 | 0.83 | DRD1 (0.35) | ALDH1A3DRD1HSD17B10NPC1GAA | |
| SCHEMBL11682199 | 0.83 | ALDH1A3 (0.38) | ALDH1A3TYRHSD17B10AHRERN1 | |
| SCHEMBL3150404 | 0.80 | DRD1 (0.33) | DRD1HSD17B10 | |
| SCHEMBL29342799 | 0.76 | ALDH1A1 (0.45) | ALDH1A3HSD17B10GAAMAPTHPGD | |
| SCHEMBL29955117 | 0.76 | AHR (0.48) | AHRERN1MAPTKMT2A | |
| SCHEMBL2012634 | 0.76 | AHR (0.48) | AHRERN1MAPTKMT2A | |
| SCHEMBL3150400 | 0.75 | SOD1 (0.35) | DRD1HSD17B10MAPT | |
| SCHEMBL3150395 | 0.72 | NOTUM (0.35) | HSD17B10AHRERN1NPC1GAA | |
| SCHEMBL3162925 | 0.71 | NOTUM (0.46) | HSD17B10AHRNPC1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803954-B2 | Competitive and selective inhibitors of trypsin-like serine proteases involved in hemostasis; anticoagulants; Ph(3-Cl)(5-OCHF2) (R)CH(OH)C(O)-Aze-Pab(OMe); oral administration; gelling matrix modified-release system | ASTRAZENECA AB (SE) | 2010-09-28 | — | — | US | disclosed |
| US-7781424-B2 | a time-release composition comprising antithrombins such as (2S)-1-[(2R)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-N-[[4-[(Z)-N'-methoxycarbamimidoyl]phenyl]methyl]azetidine-2-carboxamide, hydroxy propyl methyl cellulose and sodium stearyl fumarate as a lubricant; cardiovascular disorder | ASTRAZENECA AB (SE) | 2010-08-24 | — | — | US | disclosed |
| US-7763597-B2 | Salts | ASTRAZENECA AB (SE) | 2010-07-27 | — | — | US | disclosed |
| EP-2186800-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | Astra Zeneca AB (SE) | 2010-05-19 | — | — | EP | disclosed |
| US-7700582-B2 | Pharmaceutical formulation | ASTRAZENECA AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-20100087651-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | INGHARDT TORD | 2010-04-08 | — | — | US | disclosed |
| EP-1347955-B1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | ASTRAZENECA AB (SE) | 2010-03-17 | — | — | EP | disclosed |
| US-7645751-B2 | Mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA (SE) | 2010-01-12 | — | — | US | disclosed |
| EP-2055696-A1 | Acid addition salts of mandelic acid derivatives | AstraZeneca AB (SE) | 2009-05-06 | — | — | EP | disclosed |
| EP-1513806-B1 | Sulphonic acid salts of mandelic acid derivatives | ASTRAZENECA AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| US-20040242536-A1 | controlled-release mixtures of plant extracts, gelation polymers and drugs such as ximelagatran, used for prophylaxis of cardiovascular disorders | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| EP-1401502-A1 | PHARMACEUTICAL FORMULATION | AstraZeneca AB (SE) | 2004-03-31 | — | — | EP | disclosed |
| US-20040019033-A1 | Mandelic acid derivatives and their use as throbin inhibitors | ASTRAZENECA AB (SE) | 2004-01-29 | — | — | US | disclosed |
| WO-2003101423-A1 | IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003101424-A1 | MODIFIED RELEASE PHARMACEUTICAL FORMULATION | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003101957-A1 | NEW SALTS | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003101956-A1 | PHARMACEUTICAL COMBINATION | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| EP-1347955-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | AstraZeneca AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| WO-2003000293-A1 | PHARMACEUTICAL FORMULATION | ASTRAZENECA AB (SE) | 2003-01-03 | — | — | WO | disclosed |
| WO-2002044145-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | ASTRAZENECA AB (SE) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242536-A1 | controlled-release mixtures of plant extracts, gelation polymers and drugs such as ximelagatran, used for prophylaxis of cardiovascular disorders | GANC, PYGM, F12 | ALDH1A3 4700/4885DRD1 4134/4885TYR 1864/4885 |
| US-20040019033-A1 | Mandelic acid derivatives and their use as throbin inhibitors | ADAMTS1, ADAMTS13, ADAMTS7 | ALDH1A3 3269/4885DRD1 1225/4885TYR 595/4885 |
| US-20100087651-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | TFPI, F2R, F2 | ALDH1A3 1421/4885DRD1 3371/4885TYR 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.